Literature DB >> 29315675

Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy.

Changmai Chen1, Zhenjun Yang1, Xinjing Tang1.   

Abstract

Gene-based therapy is one of essential therapeutic strategies for precision medicine through targeting specific genes in specific cells of target tissues. However, there still exist many problems that need to be solved, such as safety, stability, selectivity, delivery, as well as immunity. Currently, the key challenges of gene-based therapy for clinical potential applications are the safe and effective nucleic acid drugs as well as their safe and efficient gene delivery systems. In this review, we first focus on current nucleic acid drugs and their formulation in clinical trials and on the market, including antisense oligonucleotide, siRNA, aptamer, and plasmid nucleic acid drugs. Subsequently, we summarize different chemical modifications of nucleic acid drugs as well as their delivery systems for gene-based therapeutics in vivo based on nucleic acid chemistry and nanotechnology methods.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  antisense oligonucleotides; chemical modifications; gene delivery; gene-based therapeutics; nucleic acid drugs; precision medicine; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29315675     DOI: 10.1002/med.21479

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  18 in total

Review 1.  Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells.

Authors:  Victoria Lm Herrera; Aaron H Colby; Nelson Ruiz-Opazo; David G Coleman; Mark W Grinstaff
Journal:  Nanomedicine (Lond)       Date:  2018-09-11       Impact factor: 5.307

2.  Charge-Conversion Strategies for Nucleic Acid Delivery.

Authors:  Kingshuk Dutta; Ritam Das; Jewel Medeiros; Pintu Kanjilal; S Thayumanavan
Journal:  Adv Funct Mater       Date:  2021-03-31       Impact factor: 19.924

3.  [Application of tetrahedral framework nucleic acids in the treatment of osteoarthritis].

Authors:  Shuai Li; Haibo Si; Bin Shen
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-04-15

4.  What's Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics.

Authors:  Ritam Das; Pintu Kanjilal; Jewel Medeiros; S Thayumanavan
Journal:  Bioconjug Chem       Date:  2022-04-04       Impact factor: 6.069

Review 5.  The growth of siRNA-based therapeutics: Updated clinical studies.

Authors:  M May Zhang; Raman Bahal; Theodore P Rasmussen; José E Manautou; Xiao-Bo Zhong
Journal:  Biochem Pharmacol       Date:  2021-01-26       Impact factor: 6.100

Review 6.  Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases.

Authors:  Irene Marafini; Giovanni Monteleone
Journal:  Biologics       Date:  2020-06-15

Review 7.  Selenium as a pleiotropic agent for medical discovery and drug delivery.

Authors:  Baozhang Guan; Ruiling Yan; Ruiman Li; Xingwang Zhang
Journal:  Int J Nanomedicine       Date:  2018-11-14

Review 8.  DNA Modified with Boron⁻Metal Cluster Complexes [M(C₂B₉H11)₂]-Synthesis, Properties, and Applications.

Authors:  Agnieszka B Olejniczak; Barbara Nawrot; Zbigniew J Leśnikowski
Journal:  Int J Mol Sci       Date:  2018-11-07       Impact factor: 5.923

9.  Multimerized self-assembled caged two-in-one siRNA nanoparticles for photomodulation of RNAi-induced gene silencing.

Authors:  Changmai Chen; Nannan Jing; Zhongyu Wang; Yu Zhang; Wei Chen; Xinjing Tang
Journal:  Chem Sci       Date:  2020-10-12       Impact factor: 9.825

Review 10.  Potential Inherent Stimulation of the Innate Immune System by Nucleic Acid Aptamers and Possible Corrective Approaches.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2018-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.